AZUR-2: Perioperative Dostarlimab in Patients with dMMR/MSI-H Resectable Colon Cancer

Full Title
Protocol 219606: A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Study Treatment
Perioperative treatment with anti-PD1 monoclonal antibody dostarlimab

Eligibility/Info
- Pathologically confirmed resectable (T4N0 or Stage III) colon adenocarcinoma
- Mismatch repair deficient or MSI-High
- No history of treatment

Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage

Need More Information?

Our team is here to help answer your questions and guide you through your options.